Pfizer Share Price in Focus: Quant Mutual Fund Buys 0.58% Stake for Rs 131.25 Crore at Rs 4,899.97 Per Share

August 21, 2026
Posted by: Kunal Singla
Category: Market

PFIZER CMP: Rs 4,920. 20-DMA: Rs 4,849.97. RSI: 56.9. Quant MF bought 2.67L shares at Rs 4,899.97 = Rs 131.25 cr. Prior stake: 2.22% (Jun 2026).

Quick Answer

Pfizer India share price is in focus after Sandeep Tandon-founded Quant Mutual Fund acquired an additional 2.67 lakh shares at Rs 4,899.97 per share for Rs 131.25 crore, representing a 0.58% stake in Pfizer’s paid-up equity. Quant Mutual Fund held a 2.22% stake in Pfizer as of the June 2026 shareholding pattern. This additional purchase would raise Quant MF’s holding to approximately 2.80%, signalling strong conviction in Pfizer India’s business trajectory.

Table of Contents

Quant MF’s Pfizer Stake Purchase: Transaction Details

Parameter	Detail
Buyer	Quant Mutual Fund (Sandeep Tandon)
Shares Acquired	2.67 lakh (0.58% stake)
Price Per Share	Rs 4,899.97
Total Value	Rs 131.25 crore
Prior Holding (Jun 2026)	2.22% stake
Estimated Holding After Buy	~2.80%

Click Here – Get Free Investment Predictions

Pfizer Share Price and Technical Setup

Pfizer share price at Rs 4,920 is above its 20-DMA of Rs 4,849.97, with RSI at 56.9 — a healthy uptrend setup without overbought conditions. Quant MF’s purchase at Rs 4,899.97 — below the current market price of Rs 4,920 — was likely a block deal transacted at a modest discount to the prevailing market rate. Pfizer is part of the Nifty Pharma index and benefits from India’s growing healthcare consumption and the phased price revision cycle for domestic pharmaceutical products.

Screen Pfizer on Univest Screener for Live Fundamentals

Why Is Quant MF Bullish on Pfizer India?

Quant Mutual Fund, known for its quantitative and data-driven approach to stock selection under Sandeep Tandon, has been consistently adding to its Pfizer India position. Pfizer India markets branded prescription medicines and OTC products, with a strong portfolio in antibiotics, hospital products, and pain management. India’s pharma sector benefits from rising domestic healthcare spending and the government’s push for affordable medicine access.

Download the Univest iOS App or Univest Android App to track Pfizer and pharma sector stocks live.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

Why is Pfizer share price in focus today?

Ans. Pfizer share price is in focus after Quant Mutual Fund acquired 2.67 lakh additional shares at Rs 4,899.97 per share for Rs 131.25 crore, representing a 0.58% stake. Quant MF held a 2.22% stake in Pfizer as of June 2026 and this purchase raises its estimated holding to approximately 2.80%.

What is Pfizer share price today on August 21, 2026?

Ans. Pfizer closed at Rs 4,920 on August 20, 2026, above its 20-DMA of Rs 4,849.97. RSI stands at 56.9, indicating neutral-to-mild bullish momentum. Quant MF bought shares at Rs 4,899.97, slightly below the closing market price.

How much Pfizer stake does Quant MF now hold?

Ans. Quant Mutual Fund held 2.22% of Pfizer India as of the June 2026 shareholding pattern. The purchase of an additional 0.58% stake raises its estimated total holding to approximately 2.80%, making it one of the larger institutional shareholders in Pfizer India.

What is Pfizer India’s business?

Ans. Pfizer India markets branded prescription medicines and OTC products in India. Its portfolio includes antibiotics, cardiovascular drugs, pain management products, hospital pharmaceuticals, and consumer healthcare products. Pfizer is a subsidiary of the global pharmaceutical giant Pfizer Inc.

Is Pfizer a good investment after Quant MF’s stake purchase?

Ans. This article is for educational purposes and is not investment advice. Quant MF’s purchase is a positive institutional signal. Pfizer’s RSI of 56.9 and position above its 20-DMA suggest a healthy technical setup. Evaluate the company’s financials and consult a SEBI-registered advisor before investing.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.